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IgG4 cholangiopathy can involve any level of the biliary tree which exhibits sclerosing cholangitis or pseudotumorous hilar
lesions. Most cases are associated with autoimmune pancreatitis, an important diagnostic clue. Without autoimmune pancreatitis,
however,thediagnosisofIgG4-cholangiopathyischallenging.Indeedsuchcaseshavebeentreatedsurgically.IgG4-cholangiopathy
should be diagnosed based on serological examinations including serum IgG4 concentrations, radiological features, and
histological evidence of IgG4+ plasma cell inﬁltration. Steroid therapy is very eﬀective even at disease relapse. A Th2-dominant
immuneresponseortheactivationofregulatoryTcellsseemstobeinvolvedintheunderlyingimmunereaction.Itisstillunknown
whyIgG4levels arespeciﬁcally elevated inpatientswiththisdisease.IgG4 mightbesecondarily overexpressedbyTh2orregulatory
cytokines given the lack of evidence that IgG4 is an autoantibody.
1.Introduction
IgG4-related disease is a unique systemic inﬂammatory con-
dition characterized by tumorous swelling of aﬀected organs
and high-serum IgG4 concentrations [1–3]. Autoimmune
pancreatitis is a prototype of IgG4 disease as Hamano et al.
described in a landmark paper in 2001 [4]. Further studies
have conﬁrmed that IgG4-related disease can involve a vari-
etyoforgansincludingthesalivaryglands(chronicsclerosing
sialadenitis)[5,6],lacrimalglands(Mikulicz’sdisease)[7,8],
and retroperitoneum (retroperitoneal ﬁbrosis) [9, 10]. The
bile duct lesion is called IgG4-related sclerosing cholangitis
(IgG4-SC) [11] or IgG4-associated cholangitis [12, 13] (the
former is used hereafter). Since we reported that IgG4-SC is
a distinct entity which should be diﬀerentiated from primary
sclerosing cholangitis (PSC) [11], clinical and pathological
features have been clariﬁed [12, 13]. In this paper, we
describe the concept, pathology, diﬀerential diagnosis, and
pathogenesis of IgG4-SC.
2. Spectrumof IgG4Cholangiopathy
The relationship between IgG4-SC and autoimmune pan-
creatitis is summarized in Table 1. IgG4-SC can manifest
as diﬀuse sclerosing cholangitis or a hilar pseudotumourous
mass [11] .T h ef o r m e rs h o u l db ed i ﬀerentiated from PSC,
whereas the latter radiologically resembles hilar cholangio-
carcinoma [14]. Of note is that most case of IgG4-SC are
associated with autoimmune pancreatitis. A study by the
Mayo Clinic found that only 4 of 53 patients (7.5%) with
IgG4 cholangiopathy had cholangitis without autoimmune
pancreatitis [13]. Whether or not IgG4-SC can involve
only peripheral small bile ducts like small-duct PSC is an
interesting issue. Given that a recent study revealed that
peripheral IgG4 cholangiopathy was always associated with
large duct lesions [15], it seems safe to assume that IgG4-SC
predominantly aﬀects large bile ducts, which are detectable
by cholangiographic or radiological examinations.
Recent papers have introduced IgG4-related autoim-
munehepatitis[16],whichaccountsfor3%ofcasesoftype1
autoimmune hepatitis in the Japanese population [17]. The
term IgG4 hepatitis should be only used for patients who do
not have radiological biliary abnormalities and are found to
have chronic hepatitis based on liver biopsies. Given that one
cases of IgG4 hepatitis was complicated later by sclerosing
cholangitis during followup [17], IgG4 hepatitis might also
belong to a spectrum of IgG4 cholangiohepatitis.2 International Journal of Hepatology
3.ClinicalFeaturesandAutoantibodies
In our experience, patients with IgG4-SC usually present
with obstructive jaundice due to a pancreatic head mass
(autoimmune pancreatitis) or severe biliary stricture [12,
13]. Other patients are sometimes discovered to have IgG4-
SC during a workup for other IgG4-related conditions
such as sialadenitis, retroperitoneal ﬁbrosis and kidney
lesions. Weight loss or new-onset diabetes mellitus due to
pancreatitis is another potential symptom.
Patients with IgG4 disease share serological abnormali-
ties irrespective of the organ of origin. There is no doubt that
elevated serum IgG4 levels are the most speciﬁc indicator.
Other sensitive but not speciﬁc markers include hyper γ-
globulinemia (observed in 50% of patients), hyper IgG (60–
70%), antinuclear antibodies (40–50%), rheumatoid factor
(20%), and eosinophilia (15–25%) [18, 19]. Autoantibody
against SS-A (Ro) or SS-B (La), antimitochondria antibody,
and antineutrophilic cytoplasmic antibody (ANCA) are all
exceptional (<5%) [18, 19].
S t u d i e so na u t o i m m u n ep a n c r e a t i t i sh a v ep r o v i d e df u r -
ther data on autoantibodies which might participate in
the pathogenesis. Antibodies against lactoferrin (LF) and
carbonic anhydrase (CA) II are frequently detected in cases
of autoimmune pancreatitis (73% and 54%, resp.) [20].
Interestingly, a strong positive correlation between increases
in serum IgG4 levels and anti-CA-II antibody levels has
been reported [21]. Anti-CA-IV, another autoantibody, was
detected in 10 of 29 (34%) patients with autoimmune
pancreatitis [22]. Given that LF and CAs are expressed in
some exocrine organs, these autoantibodies may be related
to systemic manifestations of IgG4-related disease. Of note
is that autoantibodies of the IgG4 subclass have not been
detected in patients with IgG4-related disease so far.
4.Diagnosis
4.1. Surgical Cases. It is not diﬃcult to make a diagnosis
of IgG4-SC if surgically resected specimens are available.
The gold standard for the diagnosis of IgG4-SC is histology
including characteristic features on H&E and extensive inﬁl-
tration by IgG4+ plasma cells on immunostaining. Patho-
l o g i c a lf e a t u r e sc a nb es u m m a r i z e da sf o l l o w s :( 1 )d i ﬀuse
lymphoplasmacytic inﬁltration, (2) storiform ﬁbrosis, (3)
obliterative phlebitis, (4) eosinophilic inﬁltration, and (5)
numerous IgG4+ plasma cells [11, 23]. Features unusual
for IgG4-SC are neutrophilic inﬁltration with or without
abscesses, xanthogranulomatous change, and mucosal ero-
sive change. Obliterative phlebitis is a ﬁnding characteristic
forIgG4-relateddiseaseirrespectiveoftheorganaﬀected.We
speculate that endothelium may express chemotactic factors,
but this has not been examined so far.
4.2. Patients with Autoimmune Pancreatitis. Serology, imag-
ing, other organ involvement, and biopsy need to be
considered for the diagnosis of nonsurgical cases. Given
that most patients (>90%) with IgG4-SC have autoimmune
pancreatitis, it seems most important to examine changes
in the pancreas. Autoimmune pancreatitis is radiologically
suspected in most cases, and the diagnosis can be con-
ﬁrmed by the serological examination of IgG4. Histological
detection of IgG4+ plasma cells is usually not necessary
for cases showing typical radiological features (sausage-
like diﬀuse swelling, peripancreatic capsule-like rim, and
irregular narrowing of the pancreatic duct) [24] and high-
serum IgG4 levels. But, if there are any unusual features on
imaging or IgG4 levels are not elevated, biopsies should be
consideredtodetectIgG4+ plasmacells.Mostinstitutionsuse
135 or 140mg/dL as a cut-oﬀ point for serum IgG4 levels,
with more than 300mg/dL being highly speciﬁc for IgG4-
related disease [4, 25].
4.3. Patients without Autoimmune Pancreatitis. It is challeng-
ing to diagnose IgG4-SC not associated with pancreatitis. In
fact, most patients have been surgically treated for suspected
biliary malignancy [13]. In our experience, detecting IgG4+
plasma cell is recommended even if the patients have high-
serum IgG4 concentrations. Three potential approaches
have been proposed to detect inﬁltration by IgG4+ plasma
cells. Vater’s ampulla biopsy is least invasive and techni-
cally easiest, and especially useful for patients discovered
endoscopically to have ampullary swelling [26–29]. Another
potential approach is a liver needle biopsy which can detect
IgG4+ plasma cells inﬁltrating into peripheral small portal
tracts [15, 30, 31]. This is particularly useful for patients
with intrahepatic biliary abnormalities on cholangiograms,
but not useful for patients with only intrapancreatic bile
duct stricture [15]. The last choice is a bile duct biopsy,
the usefulness of which might depend on the ability and
experience of the endoscopists [29]. The biggest advantage
of this method is that not only IgG4+ plasma cells but also
other histological features such as storiform ﬁbrosis and
eosinophilic inﬁltration are detectable [29]. The speciﬁcity
and sensitivity of the diagnosis by these three biopsies are
summarized in Table 2. Normally, more than 10 IgG4+
plasma cells are used as the diagnostic threshold for biopsy
samples.
4.4. Steroid Trial. There is no international consensus
regarding diagnostic steroid trials for IgG4-related disease.
Some institutions use steroid trials for the diagnosis [32–
34], whereas other groups, especially from Japan, are against
doing so [35]. Given that IgG4-SC needs to be diﬀerentiated
from malignant tumours (cholangiocarcinoma) diﬀerent
from other typical autoimmune diseases, much attention
should be paid to diagnostic steroid trials.
5. DifferentialDiagnosis
5.1. PSC. IgG4-SC must be diﬀerentiated from PSC given
that the steroid responsiveness is completely diﬀerent. These
two entities are histologically distinct. Large bile ducts
aﬀected by IgG4-SC show transmural inﬂammation with
storiform ﬁbrosis and obliterative phlebitis (Figure 1),
whereas inﬂammation is more extensive on the luminal
side with erosion or xanthogranulomatous changes in PSC
[11]. Clinically, a young age (<40 years) and history ofInternational Journal of Hepatology 3
Table 1: Disease spectrum of IgG4 pancreato-cholangiopathy and diﬀerential diagnosis.
IgG4-related pancreato-cholangiopathy Diﬀerential diagnosis
Autoimmune pancreatitis without bile duct involvement Pancreatic cancer
Autoimmune pancreatitis with IgG4 cholangitis Pancreatic cancer and cholangiocarcinoma
IgG4-related sclerosing cholangitis Primary sclerosing cholangitis
IgG4-related sclerosing cholangitis with hilar pseudotumor Hilar cholangiocarcinoma
(a) (b) (c)
(d) (e) (f)
Figure 1: Histopathology of IgG4-related sclerosing cholangitis. The surgical specimens show diﬀuse inﬂammatory cell inﬁltration with
ﬁbrosis involving peribiliary glands (a), obliterative phlebitis (b), and inﬁltration of many IgG4+ plasma cells (c). The liver needle biopsy
reveals portal inﬂammation (d), bile duct damage (e), and IgG4+ plasma cells (f).
Table 2: Sensitivity and speciﬁcity of detection of IgG4+ plasma












Bile duct biopsy 52% 97% [29]
inﬂammatory bowel disease are features suggestive of PSC,
whereas IgG4-SC is more likely in patients with other
sclerosing lesions including autoimmune pancreatitis and
retroperitoneal ﬁbrosis. Serologically, IgG4 levels are most
useful, but it should be noted that 9% of PSC patients
show elevated IgG4 levels [36]. Positivity for ANCA is
suggestive of PSC. Eosinophilia is similarly detectable in
both diseases. Nakazawa et al. reported that PSC and IgG4-
SC can be diﬀerentiated based on a detailed examination
of cholangiograms [37]. Liver biopsy is also useful. Inﬁl-
tration of IgG4+ plasma cells or the presence of periportal
“ﬁbroinﬂammatory nodules [30]” in needle biopsy samples
is suggestive of IgG4-SC (Figure 1), whereas ductopenia and
periductal concentric ﬁbrosis are more commonly seen in
PSC [15, 31]. It is still unclear whether or not PSC can be
diﬀerentiated from “burned-out” IgG4-SC.
5.2. PSC with Many IgG4+ Plasma Cells. Zhang et al.
[38] examined tissue inﬁltration of IgG4+ plasma cells in
explanted liver with PSC. Twenty-three of 98 livers (23%)
showed more than 10 IgG4+ cells per HPF which might be
less speciﬁc given that most IgG4-related lesions show more
than 100 IgG4+ cells/HPF in surgical specimens. In addition,
another group revealed that 2 out of 41 (5%) explanted livers
withPSCshowedmorethan100IgG4+ cells/HPF[39].These
two studies suggested that explanted livers with PSC can
sometimes show moderate degrees of IgG4+ cell inﬁltration4 International Journal of Hepatology
(>10 cells/HPF) and rarely exhibit marked inﬁltration (>100
cells/HPF) around large bile duct lesions. Importantly, the
other histological features of these cases were not typical of
IgG4-SC but consistent with PSC [38, 39]. The histological
diagnosisofIgG4-SCisnotenoughjustbasedonthenumber
of IgG4+ plasma cells.
5.3. Follicular Cholangitis. This is a rare disease entity
characterized by numerous lymphoid follicles around hilar
or perihilar bile ducts [40, 41]. Most patients reported
so far underwent surgical resection on suspicion of hilar
cholangiocarcinoma. Follicular cholangitis is diﬀerent from
PSC in that the inﬂammatory cell inﬁltration is more
extensive and biliary epithelial damage is not conspicuous.
IgG4+ plasma cell inﬁltration or obliterative phlebitis is
usually not conspicuous, diﬀerent from IgG4-SC [40].
5.4. Hilar Cholangiocarcinoma. In our experience, hilar
cholangiocarcinoma is the most important and diﬃcult
diﬀerential diagnosis of IgG4-SC in the clinical ﬁeld,
particularly for patients without autoimmune pancreatitis.
Radiological features of IgG4-SC sometimes resemble those
of hilar cholangiocarcinoma [14]. Serum IgG4 levels can be
mildly elevated in patients with cholangiocarcinoma, but
titers of more than 300 mg/dL are highly suggestive of
IgG4-SC. As described above, histological examination to
detect IgG4+ cell inﬁltration is needed for patients without
autoimmune pancreatitis.
6. Treatment
IgG4-SC responds dramatically to steroid therapy the same
as other IgG4-related lesions. This is one signiﬁcant diﬀer-
ence from PSC [12, 13]. At the moment, it is diﬃcult to
conclude the recommended dose and duration of steroid
therapy for IgG4-SC because of a lack of published data. A
Japanese study on autoimmune pancreatitis recommended
an initial dose of 0.6 mg/kg/day, which was then reduced to
a maintenance dose over a period of 3–6 months [42]. In
that study, disease relapses appeared to be reduced but not
eliminated by maintenance treatment with low-dose steroid
[42]. Rituximab is a potential treatment for steroid-resistant
autoimmune pancreatitis or IgG4-SC [43].
7. Pathogenesis
Recent papers have provided data suggesting that the Th2-
type immune response is activated in IgG4-related disease
including IgG4-SC [44–48]. Quantitative real-time PCR
using RNA extracted from frozen tissue of aﬀected organs
including bile ducts revealed signiﬁcantly higher ratios of
IL-4/IFN-γ,I L - 5 / I F N - γ, and IL-13/IFN-γ in IgG4-related
disease tissues than in tissues from patients with classical
autoimmune diseases [49]. Lymphocytes expressing IL-4
were clearly demonstrated by in situ hybridization. Recent
papers also showed that peripheral blood mononuclear cells
collected from patients with IgG4-related disease produced
predominantly Th2-type cytokines such as IL-4, IL-5, IL-10,
and IL-13 after T-cell stimulation.
Interestingly, the number of regulatory T-cells (Tregs)
is characteristically increased in both tissue and blood
of patients with IgG4-related disease. Our investigation
revealed that the mRNA expression of forkhead box P3
(Foxp3, a Tregs-speciﬁc transcriptional factor) was higher
in IgG4-related disease than in classical autoimmune dis-
eases. Two regulatory cytokines, IL-10 and transforming
growth factor-β (TGF-β), are signiﬁcantly overexpressed
[49, 50]. Furthermore, CD4+CD25+Foxp3+ Tregs could
be detected within aﬀected tissues by immunohistochem-
istry, in numbers signiﬁcantly higher than in autoimmune
and nonautoimmune disease controls. The number of
Foxp3+ cells was signiﬁcantly correlated with the number
of IgG4+ plasma cells in IgG4-related cholangitis [51].
Miyoshi et al. examined the number of Tregs in the
blood and reported that the number of CD4+CD25high
Tregs was signiﬁcantly higher in patients with AIP than
in patients with chronic pancreatitis and was correlated
with the level of IgG4 in serum [52]. The number of
na¨ ıve Tregs was signiﬁcantly decreased. They speculated
that hyporeaction of na¨ ı v eT r e g sm i g h tb ei n v o l v e di nt h e
development of IgG4-related disease, whereas hyperreaction
of CD4+CD25high Tregs could reﬂect IgG4-related disease
progression [52].
The possible involvement of H pylori in the pathogen-
esis of AIP was reported in 2005 [53]. Gastric H. pylori
infection triggers AIP in genetically predisposed subjects
via molecular mimicry between human CA-II and alpha-
carbonic anhydrase of H. pylori [54]. Frulloni et al. found
that 94% of patients with AIP had antibodies against a
plasminogen-binding protein of H. pylori [55]. The amino
acid sequence of the plasminogen-binding protein exhibited
homology with that of the ubiquitin-protein ligase E3
component n-recognin 2, an enzyme expressed in pancreatic
acinar cells. However, the involvement of H. pylori in
the pathogenesis of other IgG4-related lesions has not
been reported so far.
8. Conclusion
IgG4-SC is a unique cholangiopathy which should be
diﬀerentiated from classical PSC or biliary malignancy.
An underlying immune response might be mediated by
predominantly Th2 or regulatory cytokines.
Abbreviations
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